Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1534 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Sylentis Concludes SYL040012 Phase I Trial

Sylentis claimed that the trial result was positive. In the trial, the patients demonstrated local and systemic tolerance to SYL040012. The trial’s endpoint was to determine the tolerance

Genentech Files BLA For Trastuzumab-DM1

Genentech’s filing of BLA is based on T-DM1 Phase II study results, which showed T-DM1 shrank tumors in one-third of women who had received on average seven prior